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Abstract
Background: To study whether and how c-MYC expression determines response to radio- and chemotherapy in
childhood medulloblastoma (MB).
Methods: We used DAOY and UW228 human MB cells engineered to stably express different levels of c-MYC, and
tested whether c-MYC expression has an effect on radio- and chemosensitivity using the colorimetric 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay, clonogenic
survival, apoptosis assays, cell cycle analysis, and western blot assessment. In an effort to validate our results, we
analyzed c-MYC mRNA expression in formalin-fixed paraffin-embedded tumor samples from well-documented
patients with postoperative residual tumor and compared c-MYC mRNA expression with response to radio- and
chemotherapy as examined by neuroradiological imaging.
Results: In DAOY - and to a lesser extent in UW228 - cells expressing high levels of c-MYC, the cytotoxicity of
cisplatin, and etoposide was significantly higher when compared with DAOY/UW228 cells expressing low levels of
c-MYC. Irradiation- and chemotherapy-induced apoptotic cell death was enhanced in DAOY cells expressing high
levels of c-MYC. The response of 62 of 66 residual tumors was evaluable and response to postoperative radio- (14
responders (CR, PR) vs. 5 non-responders (SD, PD)) or chemotherapy (23 CR/PR vs. 20 SD/PD) was assessed. c-MYC
mRNA expression was similar in primary MB samples of responders and non-responders (Mann-Whitney U test, p =
0.50, ratio 0.49, 95% CI 0.008-30.0 and p = 0.67, ratio 1.8, 95% CI 0.14-23.5, respectively).
Conclusions: c-MYC sensitizes MB cells to some anti-cancer treatments in vitro. As we failed to show evidence for
such an effect on postoperative residual tumors when analyzed by imaging, additional investigations in xenografts
and larger MB cohorts may help to define the exact function of c-MYC in modulating response to treatment.
Background
Medulloblastomas (MB) are the most common malig-
nant brain tumors of childhood and constitute 20% of
all pediatric brain tumors [1]. Progress in the treatment
of MB has been achieved in multiple areas including
neurosurgical techniques, refined dosing and delivery of
radiation, and optimized chemotherapy [2]. Tumors are
currently risk-stratified as standard risk or high risk,
depending on clinical factors such as age, extent of
resection, and presence of metastases [3].
The oncogene c-MYC is one of the most crucial and
frequently deregulated proteins in human cancers [4].
c-MYC is a regulator of S-phase entry, proliferation, and
differentiation [5], and has the ability to drive both pro-
liferation and apoptosis [4,6-8]. In situations of cellular
stress such as growth factor deprivation, hypoxia, ioniz-
ing radiation, or exposure to chemotherapy, c-MYC
deregulation may induce apoptosis [9-11]. In childhood
MB, high c-MYC mRNA expression, c-MYC gene
amplification, and low-level copy changes of c-MYC
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have been shown to indicate an unfavorable prognosis
[12-15], and c-MYC amplification will be used as a
molecular stratification factor in the future SIOP-Europe
PNET 5 and 6 MB trials.
Several studies investigating whether c-MYC alters the
response of cells to radio- and chemotherapy have
shown conflicting results [9,11,16-20]. In a recent study
we have demonstrated, using small interfering RNA
(siRNA) to inhibit c-MYC expression in D341, D425
and DAOY MB cells transiently, that c-MYC down-reg-
ulation may reduce sensitivity to radiotherapy, cisplatin,
and etoposide treatment [8]. To validate these results
and to better understand the effect of c-MYC on MB
treatment, we analyzed the response of DAOY and
UW228 MB cells engineered to stably express different
levels of c-MYC to irradiation and to a panel of che-
motherapeutic drugs. We then analyzed c-MYC mRNA
expression in formalin-fixed paraffin-embedded tumor
samples (FFPE) from well-documented patients with
postoperative residual tumor mass treated within the
prospective multi-center studies HIT’91 and HIT 2000
and compared c-MYC mRNA expression with response
to radio- and chemotherapy, as determined by neurora-
diological imaging.
Methods
Human MB cell lines
DAOY and UW228, which have not been described to
have c-MYC amplifications, were used [21,22]. DAOY wt
(wild-type), DAOY V11 (empty vector transfected), DAOY
M2 (c-MYC vector transfected), UW228 wt (wild-type),
UW228 V1 (empty vector transfected), and UW228 M13
(c-MYC vector transfected) human MB cells have been
described previously [23]. The c-MYC cDNA was cloned
downstream of the CMV immediate-early promoter [23].
In DAOY M2 and UW228 M13 cells, c-MYC mRNA
levels are 15- to 20-fold higher compared with parental or
empty vector transfected control cells [23,24]. Protein
levels are induced in parallel with mRNA expression and
this protein is functional, as shown by 1.5- to 3-fold
increases in c-MYC binding activity and transcriptional
activity, respectively [23,24]. It has been shown that
mRNA expression of DAOY M2 and UW228 M13 cells
are comparable to those seen in the upper quartile of
primary human MB tumors [23]. We verified c-MYC
expression of DAOY and UW228 cell lines by real-time
quantitative RT-PCR and western blot analysis repeatedly.
All DAOY MB cells were cultured in Richter’s zinc option
medium/10% fetal bovine serum. All UW228 MB cells
were grown in DMEM/F12, 10% fetal bovine serum (G418
was added to the medium for DAOY V11, DAOY M2,
UW228 V1, and UW228 M13 to a concentration of
500 μg/ml). All cells were incubated at 37°C in a humidi-
fied atmosphere with 5% CO2.
Western blot analysis
The protein expression of caspase-8, caspase-9, and
b-actin was assessed by Western blot analysis. In brief,
cell lysates were obtained from DAOY wt, DAOY V11,
and DAOY M2 MB cells following different treatments
(irradiation (IR), cisplatin, and etoposide). Whole-cell
pellets were lysed, 40 μg total protein was separated by
10% SDS polyacrylamide gels, and the gels were sub-
jected to immunoblotting as described previously [8,24].
Nonspecific binding sites were blocked by 3 h incuba-
tion in TBST (10 mM Tris pH 8.0, 150 mM NaCl,
0.05% Tween 20) supplemented with 5% non-fat milk
powder. Membranes were incubated overnight at 4 °C
with a 1:200 dilution of rabbit polyclonal anti-caspase-8
antibody (Santa Cruz Biotechnology; Heidelberg, Ger-
many) and with a 1:1000 dilution of rabbit polyclonal
anti-caspase-9 antibody (Cell Signaling; Allschwil, Swit-
zerland). Membranes were then washed three times at
room temperature in TBST for 30 min each time, and
bound Ig was detected using anti-isotype monoclonal
secondary antibody coupled to horseradish peroxidase
(Santa Cruz Biotechnology; Heidelberg, Germany). The
signal was visualized by enhanced chemiluminescence
ECL (Amersham Biosciences; Dübendorf, Switzerland)
and autoradiography. Immunoblotting with a 1:5000
dilution of a monoclonal primary b-actin antibody
(Sigma; Basel, Switzerland) was performed to verify
equivalent amounts of loaded protein.
Chemo- and radio-sensitivity assays
Appropriate numbers of exponentially growing MB cells
were seeded in 96-well plates. Cells were treated for
72 h with various concentrations of cisplatin, carbopla-
tin, doxorubicin, etoposide, methotrexate, or vincristine,
or were irradiated with 2, 5, or 10 Gy; using a Pantak
Therapax 300 kV X-ray unit at 0.7 Gy/min. Dosimetry
was controlled with a Vigilant dosimeter. Cell viability
of human MB cells was quantified using the colori-
metric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt
(MTS) assay 72 h after IR or after adding the che-
motherapeutic drugs [8,24]. Each experiment was per-
formed in sixplicate. All assays were repeated as
independent experiments at least twice.
Clonogenic survival assay
To assess clonogenic survival, the number of single
seeded cells was adjusted to obtain around 100 colonies
per cell culture dish with a given treatment, as described
previously [8]. After exposure to the different treat-
ments, cells were maintained at 37 °C in a humidified
atmosphere containing 5% CO2 and allowed to grow for
9-10 days before fixation in methanol/acetic acid
(75%:25%) and staining with Giemsa. Colonies with
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more than 50 cells were counted. Each experiment was
performed in triplicate. All clonogenic assays were
repeated as independent experiments at least twice.
Cell cycle analysis
After treating the human MB cells with IR or cytotoxic
drugs, both floating and adherent cells were collected.
After washing twice in phosphate-buffered saline (PBS),
the cells were stained with a solution containing 50 μg/
ml propidium iodide (Becton-Dickinson; Allschwil,
Switzerland) and 100 U/ml RNase A (Qiagen; Hom-
brechtikon, Switzerland) in PBS for 30 min at room
temperature. The percentage of cells in the different
phases of the cell cycle was assessed by evaluating DNA
content as described previously [8,24].
Apoptosis assay
A photometric enzyme-immunoassay (Cell Death Detec-
tion ELISA; Roche Diagnostics, Basel, Switzerland) was
used for the quantitative determination of cytoplasmic
histone-associated DNA fragments, as described else-
where [8,24]. Each experiment was done in triplicate.
MB patients and therapy
Children with MB were treated within the two consecu-
tive prospective multicenter trials HIT’91 [25] and HIT
2000 (ClinicalTrials.gov/NCT00303810). In total, 280
patients with histologically proven MB, diagnosed
between 1991 to 1997, aged 3 to 18 years, were rando-
mized to treatment by postoperative chemotherapy fol-
lowed by radiotherapy versus postoperative radiotherapy
followed by maintenance chemotherapy (HIT’91) [25].
FFPE tumor samples to assess c-MYC mRNA expression
were available from 31 of 81 MB patients with post-
operative residual tumor.
Children with non-metastatic MB diagnosed since Jan-
uary 2001, aged 4 to 21 years, were treated by post-
operative radiotherapy followed by maintenance
chemotherapy [25-27] (HIT 2000 AB4-SIOP PNET 4),
and patients with metastatic MB by postoperative che-
motherapy, two cycles of HIT-SKK [28], followed by
radiotherapy and maintenance chemotherapy [25-27]
(MET-HIT 2000 AB4), as described previously [29].
FFPE tumor samples to assess c-MYC mRNA expression
were available from 37 of 105 MB patients with post-
operative residual tumor (out of 275 MB patients, at the
time of analysis). All tumors - analyzed for c-MYC
mRNA expression (n = 68) - were resected from
patients who had not received any treatment before.
Postoperative residual tumor was evaluated by MRI or
CT within 72 hours after surgery.
All institutions participating in the studies had received
approval from their institutional review boards and
informed consent was obtained from legal representatives
of patients. Staging within the studies was performed
according to Chang criteria [30]. Central histopathologi-
cal, neuroradiological, and cerebrospinal fluid (CSF)
analysis was recommended for all patients. Patients
enrolled in the studies were evaluated by neuroimaging
studies of the brain - contrast-enhanced CT, gadoli-
nium-enhanced MRI, or both - to determine the
response to radiation therapy and chemotherapy using
radiographic criteria as described previously [25,28].
Complete response (CR) was defined as complete reso-
lution of tumor as assessed by neuroimaging studies,
partial response (PR) was defined as a decrease in
tumor size by ≥ 50%, stable disease (SD) as a decrease
of less than 50% or an increase of less than 25%, and
progressive disease (PD) as an increase of ≥ 25%.
Responders were defined as children with CR/PR, and
non-responders as patients with SD/PD.
RNA isolation and quantitative reverse transcription-PCR
for c-MYC
Isolation of total RNA from FFPE tumor tissue and real-
time quantitative RT-PCR for analyses of c-MYC have
been described previously [13].
Statistical analysis
All data are expressed as mean ± standard deviation. Dif-
ferences between groups were examined for statistical sig-
nificance using the unpaired Student’s t-test. P < 0.05 was
in general considered to be significant. GraphPad Prism 4
(GraphPad Software, San Diego, California) software was
used to calculate IC50 values and their 95% confidence
intervals and to statistically compare fitted midpoints (log
IC50) of the two curves [8]. The Mann-Whitney test was
used to compare c-MYC mRNA expression of tumors
responding (CR/PR) with tumors not responding (SD/PD)
to first treatment modality (radiotherapy or chemother-
apy). SPSS Software 17.0 was used for univariate and
multivariate Cox regression analysis to investigate whether
c-MYC mRNA expression is associated with duration to
best response. c-MYC mRNA expression was scored as a
continuous variable (log10 transformed to obtain an
approximately normally distributed variable, 0.01 added if
c-MYC mRNA level was not detectable). The central
tendencies of c-MYC mRNA levels for responders and
non-responders were calculated on the basis of log-
transformed data, i.e. ratios of geometric means with 95%
confidence intervals (CI) are reported.
Results
Susceptibility of DAOY and UW228 cells expressing
different levels of c-MYC to IR, etoposide, cisplatin,
carboplatin, doxorubicin, methotrexate, and vincristine
To investigate whether the sensitivity of MB cells to radio-
and chemotherapy depend on the c-MYC expression level,
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we assessed cell viability of DAOY and UW228 human
MB cells expressing different levels of c-MYC 72 h follow-
ing irradiation with 0, 2, 5, or 10 Gy (Figure 1), or 72 h
after treatment with different concentrations of etoposide,
cisplatin, carboplatin, doxorubicin, methotrexate, or vin-
cristine (Figure 2). IR (10 Gy) decreased viability to 68.0 ±
1.9% in DAOY wt, to 63.2 ± 7.7% in DAOY V11, and to
34.7 ± 9.2% in DAOY M2 (c-MYC over-expressing) cells;
IR (10 Gy) reduced viability to 67.5 ± 2.1% in UW228 wt,
to 69.1 ± 3.5% in UW228 V1, and to 49.5 ± 5.2% in
UW228 M13 (c-MYC over-expressing) cells.
DAOY M2 and UW228 M13 cells were significantly
more susceptible to etoposide and cisplatin (p < 0.001),
DAOY M2 cells also to carboplatin (p < 0.001), and
DAOY M2 and UW228 M13 cells tend to be more
responsive (not significant) to doxorubicin and vincris-
tine when compared to corresponding empty vector
transfected cells (DAOY V11 and UW228 V1) (Figure 2).
DAOY and UW228 cells expressing different levels of
c-MYC were equally sensitive to methotrexate. In parti-
cular, DAOY M2 cells appear to be more sensitive to
IR, platins, and topoisomerase II inhibitors as deter-
mined by the MTS assay when compared with control
cells. Therefore, differences in cellular sensitivity were
further investigated using clonogenic survival assays to
determine the susceptibility of DAOY (wt, V11, and
M2) cells to IR (Figure 3A), cisplatin (Figure 3B), etopo-
side (Figure 3C), and doxorubicin (Figure 3D). The clo-
nogenic survival of DAOY M2 cells was more reduced
after IR, cisplatin, etoposide, and doxorubicin when
compared with control cells. Taken together, our results
show that c-MYC levels do affect cellular sensitivity to
IR and selected chemotherapeutics.
Irradiation-, cisplatin-, etoposide-, and doxorubicin-
induced cell cycle alteration in DAOY MB cells expressing
different levels of c-MYC
To study whether treatment-induced effects on cell
cycle progression and induction of apoptosis differ in
DAOY cells, we exposed DAOY (wt, V11, and M2) MB
cells to IR. Subsequently, the cells were cultured for up
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Figure 1 Effect of c-MYC expression on radio-sensitivity of
DAOY and UW228 MB cells. DAOY (c-MYC over-expressing) cells
(A) and less pronounced UW228 (c-MYC over-expressing) cells (B)
are more susceptible to IR as determined by MTS assay compared
with control cells (DAOY V11; UW228 V1). Values represent the
mean percentage of viability (representative from two independent
experiments) compared with non-irradiated cells ± standard
deviation (n = 6). Student’s t-test compared DAOY M2 and UW228
M13/irradiated cells vs. DAOY V11 and UW228 V1/irradiated cells
(***: P < 0.001, **: P < 0.01,*: P < 0.05).
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Figure 2 Effect of c-MYC expression on chemo-sensitivity of
DAOY and UW228 MB cells. DAOY (c-MYC over-expressing) and
to a lesser extent UW228 (c-MYC over-expressing) cells are more
susceptible to etoposide, cisplatin, carboplatin, and doxorubicin, and
are equally sensitive to methotrexate and vincristine, as determined
by MTS assay compared with control cells (DAOY wt, V11; UW228
wt, V1). Values represent the mean percentage of viability
(representative from two independent experiments) compared with
non-treated cells ± standard deviation (n = 6). The IC50 values and
their 95% confidence intervals were calculated from the regression
curve and are indicated for each data set for c-MYC- and empty
vector-transfected DAOY and UW228 cells. Differences between the
two curves are represented by P-values (P < 0.001, P < 0.01, P <
0.05, n.s. not significant).
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to 48 h and subjected to determination of cell cycle pro-
file by fluorescence activated cell sorter (FACS) analyses.
As shown in Figure 4A, all DAOY cells arrested in the
G2/M phase of the cell cycle about 24 h after irradiation
(5 Gy). The G2/M arrest did not appear to be irreversi-
ble as cells re-entered the cell cycle, as suggested by the
reappearance of a G1 peak within 48 h after IR. We
observed IR (5 Gy) mediated sub-G1 accumulation in
DAOY M2 but not in DAOY wt and DAOY V11 cells
(Figure 4A). To investigate the cell cycle response to
treatment with cisplatin, etoposide, and doxorubicin,
DAOY (wt, V11, and M2) MB cells were exposed to the
different chemotherapeutic agents under conditions
where differences in short-term toxicity were observable
(Figure 2). As shown in Figure 4B, DAOY cells initially
arrested in S-phase after 24 h and then in the G2/M
phase of the cell cycle about 48 h after cisplatin treat-
ment. On the other hand etoposide and doxorubicin
induced a G2/M-arrest in DAOY (wt, V11, and M2) MB
cells after 24-48 h of treatment (Figure 4C,D). Strikingly,
sub-G1 accumulation was more prominent in DAOY
M2 cells after exposure to the different treatments
(Figure 4A-D). In summary, IR induced a reversible
G2/M-arrest in all DAOY cells followed by re-entry into
the G1 phase. The cytotoxic drugs tested in this study
induced a transient arrest in the S-phase (cisplatin) and
in the G2/M-phase (cisplatin, etoposide, and doxorubi-
cin) in all DAOY cells. Importantly, sub-G1 accumula-
tion, which suggests apoptosis, was induced after IR and
selected cytotoxic drugs mainly in DAOY M2 cells.
Irradiation-, cisplatin-, etoposide-, and doxorubicin-
induced apoptotic cell death is increased in DAOY c-MYC
over-expressing cells
To test whether treatment-induced apoptosis differs in
DAOY (wt, V11, and M2) MB cells, apoptotic cell death
was assessed using Cell Death ELISA at 0, 24, 48, and
72 h after IR (5 Gy), cisplatin, etoposide, and doxorubi-
cin treatment under conditions where differences in
short-term cytotoxicity was detectable (Figure 2). DAOY
M2 cells are characterized by higher basal apoptotic
activity compared with DAOY wt and DAOY V11
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Figure 3 Clonogenic survival of DAOY MB cells after IR,
cisplatin, etoposide, and doxorubicin. The clonogenic survival of
DAOY (c-MYC over-expressing) cells following IR (A), cisplatin (B),
etoposide (C), and doxorubicin (D) is more compromised as
assessed by clonogenic survival assay compared with control cells
(DAOY wt, V11). Values represent the mean percentage of
clonogenic survival (representative from two independent
experiments) compared with non-irradiated or solvent-only treated
cells ± standard deviation (n = 3). Student’s t-test compared DAOY
M2/treated cells vs. DAOY V11/treated cells (***: P < 0.001, **: P <
0.01,*: P < 0.05).
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Figure 4 IR-, cisplatin-, etoposide-, and doxorubicin-mediated
effect on cell cycle progression in DAOY MB cells. Cell cycle
analysis following IR (A), exposure to cisplatin (B), etoposide (C), and
doxorubicin (D). DAOY MB cells were irradiated with 5 Gy or treated
with cisplatin (0.15 μg/ml), etoposide (0.19 μg/ml), or doxorubicin (0.02
μg/ml), and subjected to cell cycle determination by propidium iodide
staining and FACS analysis at the time points indicated. The
percentages of cells in G1, S, G2/M, and sub-G1 phases of the cell
division cycle are indicated ± standard deviation (n = 2).
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(Figure 5). After treatment with IR (5 Gy) apoptotic cell
death was induced in DAOY M2 cells in a time-
dependent manner, whereas IR (5 Gy) did not induce
apoptosis in DAOY wt and V11 cells (Figure 5A). Like-
wise, a high c-MYC level enhanced susceptibility to
cisplatin- (Figure 5B), etoposide- (Figure 5C), and doxor-
ubicin- (Figure 5D) induced apoptotic cell death in a time-
dependent manner. Chemotherapy induced apoptotic cell
death to a notably lesser extent in the parental and empty
vector-transfected DAOY cells when compared with
DAOY M2 cells. In conclusion, these results confirm that
c-MYC over-expression increases basal apoptotic activity
and the susceptibility to undergo apoptosis after treatment
with various cytotoxic agents.
c-MYC acts in synergy with irradiation, cisplatin, and
etoposide to trigger caspase-9 cleavage in DAOY c-MYC
over-expressing cells
We next investigated whether IR, cisplatin, and etopo-
side induce caspase-dependent apoptotic cell death.
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Figure 5 Effect of c-MYC expression on the apoptotic activity of DAOY MB cells after exposure to DNA-damaging agents. IR (A),
cisplatin (B), etoposide (C), and doxorubicin (D) enhance the induction of apoptotic cell death in c-MYC over-expressing DAOY cells, as
determined by Cell Death ELISA assay at the different time points indicated. Values represent the mean absorbance of cytoplasmic histone-
associated-DNA fragments ± standard deviation (n = 3). Student’s t-test compared DAOY M2/treated cells vs. DAOY V11/treated cells (***: P <
0.001, **: P < 0.01,*: P < 0.05).
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We assessed the processing of pro-caspase 8 and 9 after
IR, cisplatin, and etoposide treatment. As shown in
Figure 6A, IR (5 Gy) of DAOY (wt, V11, and M2) cells
resulted in the proteolytic cleavage of pro-caspase 9
only in DAOY M2 cells. No proteolytic cleavage of pro-
caspase 8 was detected in DAOY (wt, V11, and M2)
cells. We also assessed the effect of cisplatin and etopo-
side on the activation of pro-caspase 8 and pro-caspase
9 in DAOY (wt, V11, and M2) cells, and found that
processing of pro-caspase 9 was more pronounced in
DAOY M2 cells (Figure 6B,C). Pro-caspase 8 cleavage
was not detected in any DAOY (wt, V11, and M2) cells
after treatment with cisplatin or etoposide.
Response of postoperative residual MB tumors to radio-
and chemotherapy and outcome according to c-MYC
mRNA expression
Our in vitro experiments provide evidence that c-MYC
sensitizes MB cells to some anti-cancer treatments. In
order to investigate whether our observations might be
of clinical relevance, we analyzed whether the response
of postoperative residual tumor to radio- and che-
motherapy depends on the c-MYC mRNA expression in
MB patients. Adequate material for assessment of c-
MYC mRNA expression was available for tumors of 68
MB patients. In our current analysis we included 31 MB
patients (> 3 years of age) from our previous study [13]
with incomplete surgical resection, and an additional
37 MB patients (> 4 years of age) with incompletely
resected tumors treated within the prospective multi-
center study HIT 2000. In 66 of these patients the qual-
ity of isolated RNA, based on quality assurance
described previously [13], was sufficient for determining
c-MYC mRNA expression. The amount of c-MYC
mRNA expression was related to human cerebellum
[13] and a cut-off value of 1 was chosen to define
patient groups with high or low expression of c-MYC,
as described elsewhere [13]. Differences in overall survi-
val (OS) of 66 patients (median follow-up: 3.1 years,
median age: 7.4 years), as determined by univariable
analysis, between patients with high (n = 37) and low
(n = 29) c-MYC mRNA expression (3-year OS 46 ± 10%
versus 76 ± 10%, p = 0.10), were comparable to our pre-
vious study [13].
Neuroradiological evaluation and c-MYC mRNA
expression analysis was of sufficient quality to determine
response rate on the residual tumor, as described else-
where [25], according to c-MYC mRNA expression fol-
lowing treatment by postoperative radiotherapy (19/21
patients) and by postoperative chemotherapy (43/45
patients) (Figure 7) as reported previously [31]. c-MYC
mRNA expression in tumors from 14 responders (CR/
PR) after postoperative radiotherapy was not signifi-
cantly different compared with c-MYC mRNA expres-
sion in tumors from 5 non-responders (SD/PD) as
determined by Mann-Whitney U test (p = 0.50, ratio
0.49, 95% CI 0.008-30.0). No significant difference in
c-MYC expression was found in tumors from 23
responsive patients and c-MYC expression in tumors
from 20 non-responsive patients after postoperative che-
motherapy (Mann-Whitney U test, p = 0.67, ratio 1.8,
95% CI 0.14-23.5). The effect of c-MYC mRNA level on
time to best objective response was assessed using uni-
variate and multivariate Cox regression analysis. Among
the 66 patients with postoperative residual tumors who
B
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Figure 6 c-MYC expression modulates caspase-9 activation
after IR, cispatin, and etoposide treatment of DAOY MB cells.
IR (A) triggers caspase-9 cleavage exclusively in c-MYC over-
expressing DAOY cells. Caspase-9 cleavage is more pronounced in
DAOY M2 cells following treatment with cisplatin (B), or etoposide
(C). Cells were irradiated with 5 Gy, treated with cisplatin (0.15 μg/
ml) or with etoposide (0.19 μg/ml). Lysates were analyzed at the
indicated time points by Western blotting for caspase 8 and 9, and
b-actin. Representative blots (two independent experiments) are
shown.
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had c-MYC mRNA expression analysis, 65 were evalu-
able for best response: 3 (5%) PD, 3 (5%) SD, 8 (12%)
PR, and 51 (78%) CR. Best response was not evaluable
in one case because the quality of postoperative MRI
was insufficient. Median time to best objective response
was 0.38 years (0.07-1.34). Increasing tumor tissue c-
MYC mRNA levels were not significantly associated
with an increasing probability of objective response (p =
0.62; hazard ratio 1.04; 95% CI 0.90-1.20). In addition to
c-MYC mRNA level, age, gender, histology, and the pre-
sence or absence of metastasis were included in a multi-
variate model. No covariates were significantly
associated with time to response (data not shown).
Discussion
The impact of c-MYC (c-MYC gene amplification and
c-MYC mRNA expression) on the prognosis of MB has
been thoroughly investigated [12-14], but the effect of
c-MYC on MB standard treatment remains largely
unknown. The present study is the first to investigate the
relationship between c-MYC expression and treatment
response in MB patients and analyzes the cell-death pro-
moting effect of clinically relevant chemotherapeutic
drugs and IR on two MB cell lines engineered to stably
express different levels of c-MYC.
DAOY M2 and UW228 M13 human MB cells, stably
engineered to over-express c-MYC, proved more sensitive
to some cytotoxic drugs and IR when compared with
wild-type and empty vector transfected control cells.
A series of preclinical studies suggested that c-MYC may
sensitize a variety of cells to different treatments [9,11,16].
Over-expression of c-MYC is associated with enhanced
susceptibility to etoposide-, doxorubicin-, and cisplatin-
induced apoptosis [11], whereas loss of c-MYC expression
reduced etoposide- and doxorubicin-mediated apoptotic
cell death [17]. However, there are also reports showing
that a decrease of c-MYC level may sensitize human mela-
noma cells to cisplatin [19,20]. Our current findings, as
well as our previous study [8] using siRNA to down-
regulate c-MYC expression transiently in MB cell lines
(DAOY, D341, and D425), provide evidence that c-MYC
may increase the cytotoxicity of IR and selected che-
motherapeutic drugs to MB cells [8].
DAOY cells, engineered to express different levels of
c-MYC, showed differing sensitivity to IR, platins, etopo-
side, and were used to further investigate how c-MYC
may modulate the cellular response to IR and some che-
motherapeutic drugs. Our study shows that differences
in cell cycle alterations appear unlikely to be responsible
for the different radio- and chemo-sensitivity of DAOY
cell lines. IR and DNA-damaging chemotherapies
resulted in a comparable pattern of cell-cycle check-
point activation in the three DAOY cell lines (wt, V11,
and M2). In all DAOY cells, IR resulted in a transient
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Figure 7 c-MYC mRNA expression of responsive versus non-responsive MB tumors to postoperative radiotherapy (RT) or
chemotherapy (CTH). c-MYC mRNA expression of MB tumors responding to postoperative RT (A) or postoperative CTH (B) were not
significantly different to MB tumors failing to respond during the first postoperative treatment modality as determined by Mann-Whitney U test.
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G2/M-arrest, allowing DNA double-strand break repair
[32]. A similar G2/M-arrest (24-48h) was observed after
treatment with the topoisomerase II poisons (etoposide
and doxorubicin) in all three DAOY cell lines. Treat-
ment with cisplatin initially resulted in a transient S-
phase arrest (24 h) and subsequently in a G2/M arrest
(48 h) in all these DAOY cell lines. This observation is
in agreement with studies demonstrating that cisplatin
induces a transient S-phase arrest, followed by inhibition
of the Cdc2-cyclin A or B kinase to induce a durable
G2/M arrest [33]. A possible explanation for the differ-
ent sensitivity to DNA-damaging agents of DAOY cells
expressing various c-MYC levels is that it might be
related to differing susceptibility to the induction of
apoptosis. Interestingly, we consistently found that IR as
well as cytotoxic compounds induced an increase in the
proportion of cells in sub-G1, mainly in DAOY M2
cells. To investigate whether DAOY M2 cells are more
prone to DNA damage-induced apoptotic cell death, we
assessed the apoptotic response of DAOY (wt, V11, and
M2) cells following IR, cisplatin, etoposide, and doxoru-
bicin more quantitatively, as described elsewhere [8,24].
We found that IR-induced apoptosis was only evident in
DAOY M2 cells whereas chemotherapy-induced apopto-
sis was more prominent in DAOY M2 cells compared
with DAOY wt and DAOY V11 cells. These results are
supported by Dee et al., who demonstrated that IR
(4 Gy) failed to induce apoptotic cell death in DAOY
(wild-type) cells [34]. Furthermore, DAOY cells engi-
neered to over-express c-MYC render p53 mutant
DAOY cells [35] susceptible to the induction of apopto-
sis. High c-MYC expressing DAOY cells were also more
susceptible to chemotherapy-induced apoptosis. These
findings are supported by studies showing that c-MYC
may augment IR- and chemotherapy-induced apoptosis
[9,11,16,17]. Conversely, c-MYC down-regulation
resulted in an increase of cisplatin-induced apoptotic
cell death in human melanoma cells [19,20], suggesting
that the decisive factors influencing a cell to undergo
apoptotic cell death and how c-MYC regulates this
apoptotic response depend on the cell type [36]. In p53
mutant DAOY cell lines, c-MYC over-expression
appears to amplify the intrinsic mitochondrial, but not
the extrinsic, apoptotic pathway [36], as suggested by
the absence of pro-caspase 8 cleavage in DAOY (wt,
V11, and M2) cells and more pronounced activation of
pro-caspase 9 in DAOY M2 compared with DAOY wt
and V11 cells following IR, cisplatin, or etoposide.
In MB patients, it has been shown that high c-MYC
mRNA expression is unfavorably associated with prog-
nosis [12,13]. We analyzed whether c-MYC expression,
determined in the primary MB tumors, has an effect -
as determined by neuroradiological evaluation - on the
response of residual tumor to postoperative IR and
postoperative chemotherapy. We found that the c-MYC
mRNA expression in tumors from 14 children (74%) who
responded to postoperative IR were similar and not signifi-
cantly different from c-MYC expression in tumors from 5
patients (26%) who did not respond. The response rate of
residual tumors to postoperative IR was comparable to
response rates observed in the HIT’91 trial which reported
an objective postoperative IR response rate for residual
tumors of 73.6% [25]. c-MYC mRNA expression in tumors
from 23 responders (53%) to postoperative chemotherapy
was not significantly different from c-MYC mRNA expres-
sion in tumors from 20 non-responders (47%) [25,28]. It is
well known that MB is uniquely sensitive to chemotherapy
and radiation [2]. We therefore also investigated whether
c-MYC determines time to response but failed to
detect any influence using univariate or multivariate Cox
regression analysis.
Some care should be taken in the interpretation of the
results, since our study has several limitations. The rela-
tionship between the response to postoperative IR and
c-MYC mRNA expression was studied in only a small
number of patients (14 responders versus 5 non-respon-
ders). The relationship between chemo-response and
c-MYC mRNA expression was studied in 43 patients
(23 responders versus 20 non-responders) treated
according to two different regimens [25,29]. These
limitations, including the use of polychemotherapy,
restrict the evaluation of the effect of c-MYC mRNA
expression on responses to individual chemotherapy and
a potential relationship between an individual drug and
c-MYC mRNA expression cannot be excluded. Iba et al.
found that responders to the treatment with platinum
compounds among patients with epithelial ovarian
cancer had higher c-MYC levels compared with non-
responders, resulting in even higher survival rates [31].
Conclusions
Taken together, c-MYC moderately enhances the anti-
tumor effect of several DNA-damaging agents through
sensitization to apoptosis in c-MYC over-expressing
DAOY MB cells. These results provide important insights
into mechanisms determining the sensitivity of MB cells
to DNA-damaging agents. Although high c-MYC expres-
sion moderately sensitizes MB cells to DNA-damaging
agents, we were unable to find evidence for this effect by
analyzing neuroradiological imaging of postoperative
residual tumors. Our results provide evidence that the
unfavorable prognosis of MB patients with high c-MYC
expressing tumors may not be explicable by their poor
response to treatment, although additional validations in
xenografts and a larger MB cohort is necessary to clarify
the exact role of c-MYC in modulating treatment
response. So far, poor outcome of MB patients with high
c-MYC expressing tumors appears to be explainable by
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their aggressive clinical nature, the tendency of high c-
MYC expressing MB cells to rapid growth [8,23,37], the
fact that high c-MYC mRNA expressing MB tumors are
often associated with tumor anaplasia [23] and relapse
more frequently [12,13]. Our study shows that MB cells
expressing high c-MYC levels are sensitive to IR and some
chemotherapeutic drugs and provides evidence that a
more aggressive treatment approach might be considered
in the future to improve the outcome in those patients.
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